Therefore, the objective of this analysis was to explore whether adjunct therapy with an empagliflozin/metformin combination, as well as both drugs separately, in overweight people with type 1 diabetes with increased cardiovascular risk, could complement insulin therapy and allow for the achievement of better glycemic goals and beneficial metabolic effects. Here, INS is linked to type 1 diabetes mellitus.